NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation - NICE TAG TA429

Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation - NICE TAG TA429

1.1 Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:

  • who have had at least 1 prior therapy or

  • who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is unsuitable and

  • only when the company provides ibrutinib with the discount agreed in the patient access scheme.

https://www.nice.org.uk/guidance/ta429

Site by Devopa
© Copyright 2019 NHS. All rights reserved.